Palisade Bio (PALI) Competitors

$1.97 -0.16 (-7.51%)

Closing price 04:00 PM Eastern

Extended Trading

$1.98 +0.01 (+0.51%)

As of 05:39 PM Eastern

PALI vs. JBIO, MAZE, MPLT, OLMA, and ABCL

Should you be buying Palisade Bio stock or one of its competitors? The main competitors of Palisade Bio include Jade Biosciences (JBIO), Maze Therapeutics (MAZE), Maplight Therapeutics (MPLT), Olema Pharmaceuticals (OLMA), and AbCellera Biologics (ABCL). These companies are all part of the "pharmaceutical products" industry.

How does Palisade Bio compare to Jade Biosciences?

Jade Biosciences (NASDAQ:JBIO) and Palisade Bio (NASDAQ:PALI) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, institutional ownership, valuation, risk, analyst recommendations, media sentiment, earnings and dividends.

: Palisade Bio has higher revenue and earnings than Jade Biosciences. Jade Biosciences is trading at a lower price-to-earnings ratio than Palisade Bio, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Jade Biosciences N/A N/A -$127.41M -$4.61 N/A
Palisade Bio $250K 1,319.27 -$16.78M -$2.12 N/A
: Jade Biosciences' return on equity of -46.55% beat Palisade Bio's return on equity.
Company Net Margins Return on Equity Return on Assets
Jade Biosciences N/A -46.55% -42.99%
Palisade Bio N/A -47.76% -42.98%
: Jade Biosciences presently has a consensus target price of $31.17, indicating a potential upside of 23.38%. Palisade Bio has a consensus target price of $10.20, indicating a potential upside of 417.77%. Given Palisade Bio's higher probable upside, analysts plainly believe Palisade Bio is more favorable than Jade Biosciences.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Jade Biosciences
1 Sell rating(s)
1 Hold rating(s)

5 Buy rating(s)

2 Strong Buy rating(s)
2.89
Palisade Bio
1 Sell rating(s)

0 Hold rating(s)

6 Buy rating(s)

1 Strong Buy rating(s)
2.88
: 11.8% of Palisade Bio shares are held by institutional investors. 24.9% of Jade Biosciences shares are held by company insiders. Comparatively, 0.1% of Palisade Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
: Jade Biosciences has a beta of 1.52, indicating that its stock price is 52% more volatile than the S&P 500. Comparatively, Palisade Bio has a beta of 1.52, indicating that its stock price is 52% more volatile than the S&P 500.
: In the previous week, Jade Biosciences had 1 more articles in the media than Palisade Bio. MarketBeat recorded 4 mentions for Jade Biosciences and 3 mentions for Palisade Bio. Jade Biosciences' average media sentiment score of 0.89 beat Palisade Bio's score of 0.00 indicating that Jade Biosciences is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Jade Biosciences
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Palisade Bio
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jade Biosciences	N/A	N/A	-$127.41M	-$4.61	N/A
Palisade Bio	$250K	1,319.27	-$16.78M	-$2.12	N/A

Company	Net Margins	Return on Equity	Return on Assets
Jade Biosciences	N/A	-46.55%	-42.99%
Palisade Bio	N/A	-47.76%	-42.98%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jade Biosciences	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89
Palisade Bio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Jade Biosciences	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Palisade Bio	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Palisade Bio beats Jade Biosciences on 8 of the 14 factors compared between the two stocks.

How does Palisade Bio compare to Maze Therapeutics?

Maze Therapeutics (NASDAQ:MAZE) and Palisade Bio (NASDAQ:PALI) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, institutional ownership, valuation, risk, analyst recommendations, media sentiment, earnings and dividends.

: Palisade Bio has lower revenue, but higher earnings than Maze Therapeutics. Maze Therapeutics is trading at a lower price-to-earnings ratio than Palisade Bio, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Maze Therapeutics $167.50M 7.89 -$131.12M -$3.23 N/A
Palisade Bio $250K 1,319.27 -$16.78M -$2.12 N/A
: Maze Therapeutics' return on equity of -40.70% beat Palisade Bio's return on equity.
Company Net Margins Return on Equity Return on Assets
Maze Therapeutics N/A -40.70% -36.03%
Palisade Bio N/A -47.76% -42.98%
: Maze Therapeutics presently has a consensus target price of $66.00, indicating a potential upside of 148.49%. Palisade Bio has a consensus target price of $10.20, indicating a potential upside of 417.77%. Given Palisade Bio's higher probable upside, analysts plainly believe Palisade Bio is more favorable than Maze Therapeutics.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Maze Therapeutics
1 Sell rating(s)
0 Hold rating(s)

8 Buy rating(s)

2 Strong Buy rating(s)
3.00
Palisade Bio
1 Sell rating(s)

0 Hold rating(s)

6 Buy rating(s)

1 Strong Buy rating(s)
2.88
: 11.8% of Palisade Bio shares are held by institutional investors. 0.1% of Palisade Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
: Maze Therapeutics has a beta of 2.5, indicating that its stock price is 150% more volatile than the S&P 500. Comparatively, Palisade Bio has a beta of 1.52, indicating that its stock price is 52% more volatile than the S&P 500.
: In the previous week, Maze Therapeutics had 1 more articles in the media than Palisade Bio. MarketBeat recorded 4 mentions for Maze Therapeutics and 3 mentions for Palisade Bio. Maze Therapeutics' average media sentiment score of 0.78 beat Palisade Bio's score of 0.00 indicating that Maze Therapeutics is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Maze Therapeutics
3 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Palisade Bio
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maze Therapeutics	$167.50M	7.89	-$131.12M	-$3.23	N/A
Palisade Bio	$250K	1,319.27	-$16.78M	-$2.12	N/A

Company	Net Margins	Return on Equity	Return on Assets
Maze Therapeutics	N/A	-40.70%	-36.03%
Palisade Bio	N/A	-47.76%	-42.98%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maze Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.00
Palisade Bio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Maze Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Palisade Bio	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Maze Therapeutics beats Palisade Bio on 9 of the 16 factors compared between the two stocks.

How does Palisade Bio compare to Maplight Therapeutics?

Palisade Bio (NASDAQ:PALI) and Maplight Therapeutics (NASDAQ:MPLT) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, risk, analyst recommendations, media sentiment, earnings and profitability.

: Palisade Bio presently has a consensus target price of $10.20, indicating a potential upside of 417.77%. Maplight Therapeutics has a consensus target price of $34.43, indicating a potential upside of 23.31%. Given Palisade Bio's stronger consensus rating and higher probable upside, equities analysts plainly believe Palisade Bio is more favorable than Maplight Therapeutics.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Palisade Bio
1 Sell rating(s)
0 Hold rating(s)

6 Buy rating(s)

1 Strong Buy rating(s)
2.88
Maplight Therapeutics
1 Sell rating(s)

1 Hold rating(s)

7 Buy rating(s)

1 Strong Buy rating(s)
2.80
: In the previous week, Maplight Therapeutics had 11 more articles in the media than Palisade Bio. MarketBeat recorded 14 mentions for Maplight Therapeutics and 3 mentions for Palisade Bio. Maplight Therapeutics' average media sentiment score of 0.37 beat Palisade Bio's score of 0.00 indicating that Maplight Therapeutics is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Palisade Bio
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Maplight Therapeutics
5 Very Positive mention(s)
3 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
: 11.8% of Palisade Bio shares are held by institutional investors. 0.1% of Palisade Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
: Palisade Bio has higher revenue and earnings than Maplight Therapeutics. Palisade Bio is trading at a lower price-to-earnings ratio than Maplight Therapeutics, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Palisade Bio $250K 1,319.27 -$16.78M -$2.12 N/A
Maplight Therapeutics N/A N/A -$161.15M -$39.65 N/A
: Maplight Therapeutics' return on equity of 0.00% beat Palisade Bio's return on equity.
Company Net Margins Return on Equity Return on Assets
Palisade Bio N/A -47.76% -42.98%
Maplight Therapeutics N/A N/A N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Palisade Bio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Maplight Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Palisade Bio	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Maplight Therapeutics	5 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Palisade Bio	$250K	1,319.27	-$16.78M	-$2.12	N/A
Maplight Therapeutics	N/A	N/A	-$161.15M	-$39.65	N/A

Company	Net Margins	Return on Equity	Return on Assets
Palisade Bio	N/A	-47.76%	-42.98%
Maplight Therapeutics	N/A	N/A	N/A

Summary

Palisade Bio beats Maplight Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Palisade Bio compare to Olema Pharmaceuticals?

Palisade Bio (NASDAQ:PALI) and Olema Pharmaceuticals (NASDAQ:OLMA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, risk, analyst recommendations, media sentiment, earnings and profitability.

: Palisade Bio presently has a consensus target price of $10.20, indicating a potential upside of 417.77%. Olema Pharmaceuticals has a consensus target price of $44.40, indicating a potential upside of 203.28%. Given Palisade Bio's stronger consensus rating and higher probable upside, equities analysts plainly believe Palisade Bio is more favorable than Olema Pharmaceuticals.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Palisade Bio
1 Sell rating(s)
0 Hold rating(s)

6 Buy rating(s)

1 Strong Buy rating(s)
2.88
Olema Pharmaceuticals
1 Sell rating(s)

2 Hold rating(s)

11 Buy rating(s)

0 Strong Buy rating(s)
2.71
: In the previous week, Olema Pharmaceuticals had 3 more articles in the media than Palisade Bio. MarketBeat recorded 6 mentions for Olema Pharmaceuticals and 3 mentions for Palisade Bio. Olema Pharmaceuticals' average media sentiment score of 0.88 beat Palisade Bio's score of 0.00 indicating that Olema Pharmaceuticals is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Palisade Bio
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Olema Pharmaceuticals
2 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
: 11.8% of Palisade Bio shares are held by institutional investors. Comparatively, 91.8% of Olema Pharmaceuticals shares are held by institutional investors. 0.1% of Palisade Bio shares are held by insiders. Comparatively, 16.4% of Olema Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
: Palisade Bio has higher revenue and earnings than Olema Pharmaceuticals. Olema Pharmaceuticals is trading at a lower price-to-earnings ratio than Palisade Bio, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Palisade Bio $250K 1,319.27 -$16.78M -$2.12 N/A
Olema Pharmaceuticals N/A N/A -$162.45M -$1.86 N/A
: Olema Pharmaceuticals' return on equity of -42.95% beat Palisade Bio's return on equity.
Company Net Margins Return on Equity Return on Assets
Palisade Bio N/A -47.76% -42.98%
Olema Pharmaceuticals N/A -42.95% -38.78%
: Palisade Bio has a beta of 1.52, indicating that its share price is 52% more volatile than the S&P 500. Comparatively, Olema Pharmaceuticals has a beta of 2.05, indicating that its share price is 105% more volatile than the S&P 500.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Palisade Bio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Olema Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Palisade Bio	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Olema Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Palisade Bio	$250K	1,319.27	-$16.78M	-$2.12	N/A
Olema Pharmaceuticals	N/A	N/A	-$162.45M	-$1.86	N/A

Company	Net Margins	Return on Equity	Return on Assets
Palisade Bio	N/A	-47.76%	-42.98%
Olema Pharmaceuticals	N/A	-42.95%	-38.78%

Summary

Olema Pharmaceuticals beats Palisade Bio on 9 of the 15 factors compared between the two stocks.

How does Palisade Bio compare to AbCellera Biologics?

Palisade Bio (NASDAQ:PALI) and AbCellera Biologics (NASDAQ:ABCL) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, valuation, analyst recommendations, media sentiment, profitability and earnings.

: In the previous week, AbCellera Biologics had 5 more articles in the media than Palisade Bio. MarketBeat recorded 8 mentions for AbCellera Biologics and 3 mentions for Palisade Bio. AbCellera Biologics' average media sentiment score of 0.61 beat Palisade Bio's score of 0.00 indicating that AbCellera Biologics is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Palisade Bio
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
AbCellera Biologics
4 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
: Palisade Bio presently has a consensus target price of $10.20, indicating a potential upside of 417.77%. AbCellera Biologics has a consensus target price of $8.17, indicating a potential upside of 75.25%. Given Palisade Bio's stronger consensus rating and higher possible upside, research analysts clearly believe Palisade Bio is more favorable than AbCellera Biologics.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Palisade Bio
1 Sell rating(s)
0 Hold rating(s)

6 Buy rating(s)

1 Strong Buy rating(s)
2.88
AbCellera Biologics
1 Sell rating(s)

1 Hold rating(s)

4 Buy rating(s)

1 Strong Buy rating(s)
2.71
: Palisade Bio has higher earnings, but lower revenue than AbCellera Biologics. AbCellera Biologics is trading at a lower price-to-earnings ratio than Palisade Bio, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Palisade Bio $250K 1,319.27 -$16.78M -$2.12 N/A
AbCellera Biologics $75.13M 18.93 -$146.41M -$0.49 N/A
: 11.8% of Palisade Bio shares are held by institutional investors. Comparatively, 61.4% of AbCellera Biologics shares are held by institutional investors. 0.1% of Palisade Bio shares are held by insiders. Comparatively, 28.9% of AbCellera Biologics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
: Palisade Bio has a net margin of 0.00% compared to AbCellera Biologics' net margin of -198.37%. AbCellera Biologics' return on equity of -15.05% beat Palisade Bio's return on equity.
Company Net Margins Return on Equity Return on Assets
Palisade Bio N/A -47.76% -42.98%
AbCellera Biologics -198.37% -15.05% -10.92%
: Palisade Bio has a beta of 1.52, indicating that its stock price is 52% more volatile than the S&P 500. Comparatively, AbCellera Biologics has a beta of 1.02, indicating that its stock price is 2% more volatile than the S&P 500.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Palisade Bio	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
AbCellera Biologics	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Palisade Bio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
AbCellera Biologics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Palisade Bio	$250K	1,319.27	-$16.78M	-$2.12	N/A
AbCellera Biologics	$75.13M	18.93	-$146.41M	-$0.49	N/A

Company	Net Margins	Return on Equity	Return on Assets
Palisade Bio	N/A	-47.76%	-42.98%
AbCellera Biologics	-198.37%	-15.05%	-10.92%

Summary

Palisade Bio and AbCellera Biologics tied by winning 8 of the 16 factors compared between the two stocks.

Get Palisade Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PALI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PALI vs. The Competition

Export

Metric	Palisade Bio	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$329.82M	$3.39B	$6.25B	$11.87B
Dividend Yield	N/A	2.20%	2.73%	5.21%
P/E Ratio	-0.93	38.85	29.04	28.47
Price / Sales	1,319.27	155.51	476.61	60.92
Price / Cash	N/A	57.88	27.62	36.52
Price / Book	2.26	7.03	9.67	6.67
Net Income	-$16.78M	$23.62M	$3.55B	$332.53M
7 Day Performance	1.03%	3.68%	1.70%	2.01%
1 Month Performance	4.23%	7.16%	5.62%	9.19%
1 Year Performance	150.32%	67.05%	34.41%	39.59%

Palisade Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PALI Palisade Bio	1.9535 of 5 stars	$1.97 -7.5%	$10.20 +417.8%	N/A	$329.82M	$250K	N/A	10	News Coverage Upcoming Earnings
JBIO Jade Biosciences	3.2704 of 5 stars	$26.45 -1.5%	$31.17 +17.8%	N/A	$1.30B	N/A	N/A	20
MAZE Maze Therapeutics	3.3356 of 5 stars	$25.95 -2.0%	$66.00 +154.3%	N/A	$1.29B	$167.50M	N/A	121
MPLT Maplight Therapeutics	3.1645 of 5 stars	$30.31 -1.1%	$32.67 +7.8%	N/A	$1.29B	N/A	N/A	109	News Coverage Analyst Forecast
OLMA Olema Pharmaceuticals	2.5347 of 5 stars	$14.59 -4.6%	$44.40 +204.3%	N/A	$1.27B	N/A	N/A	70	News Coverage Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PALI) was last updated on 5/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Palisade Bio (PALI) Competitors

PALI vs. JBIO, MAZE, MPLT, OLMA, and ABCL

How does Palisade Bio compare to Jade Biosciences?

Summary

How does Palisade Bio compare to Maze Therapeutics?

Summary

How does Palisade Bio compare to Maplight Therapeutics?

Summary

How does Palisade Bio compare to Olema Pharmaceuticals?

Summary

How does Palisade Bio compare to AbCellera Biologics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PALI vs. The Competition

Palisade Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Palisade Bio (PALI) Competitors

PALI vs. JBIO, MAZE, MPLT, OLMA, and ABCL

How does Palisade Bio compare to Jade Biosciences?

Summary

How does Palisade Bio compare to Maze Therapeutics?

Summary

How does Palisade Bio compare to Maplight Therapeutics?

Summary

How does Palisade Bio compare to Olema Pharmaceuticals?

Summary

How does Palisade Bio compare to AbCellera Biologics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PALI vs. The Competition

Palisade Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools